Current status and future prospects for the use of tertiary lymphatic structures in the diagnosis and treatment of lung cancer
10.3760/cma.j.cn112434-20230226-00040
- VernacularTitle:三级淋巴结构在肺癌诊断和治疗中的应用现状和未来前景
- Author:
Shuai JIANG
1
;
Fuzhi YANG
;
Xiaoyong SHEN
Author Information
1. 复旦大学附属华东医院胸外科，上海 200003
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2023;39(11):685-691
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the malignant tumors with the highest incidence and mortality rate worldwide and has a poor prognosis. With the popularization of thin layer CT, more and more early lung cancers are being detected. In recent years, thoracoscopic technology and robotic surgery technology have been innovated, and multiple adjuvant therapies such as chemotherapy, targeted therapy and immunotherapy have progressed rapidly, providing lung cancer patients with multiple treatment options. However, the prognosis of lung cancer patients has not been significantly improved, which is related to the overall poor prognosis of lung cancer patients on the one hand, and the urgent need to find effective predictive markers for patients' prognosis, to accurately screen patients, and to carry out targeted treatment in order to improve patients' prognosis on the other hand. In this paper, we review the progress of tertiary lymphoid structures (TLSs) in lung cancer and discuss the prognostic predictive value of TLSs in lung cancer and their feasibility as biomarkers for adjuvant therapy.
